Lenacapavir Rimegepant

DHHS Adult ARV Guidelines

Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects

Potential increased risk of rimegepant adverse effects

Management

If coadministering, avoid taking a second dose of rimegepant within 48 hours